ストックスクリーナーアプリを入手
24.80
1.16%
0.26
前日終値:
$24.54
開ける：
$24.57
24時間の取引高:
18.10M
Relative Volume:
0.45
時価総額：
$141.43B
収益：
$63.32B
当期純損益:
$7.52B
株価収益率:
19.01
EPS:
1.3043
ネットキャッシュフロー:
$9.48B
1週間 パフォーマンス:
+0.30%
1か月 パフォーマンス:
+2.20%
6か月 パフォーマンス:
-6.32%
1年 パフォーマンス:
+0.14%
1日の値動き範囲:
$24.44
$24.88
1週間の範囲:
$24.44
$25.19
52週間の値動き範囲:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.82 | 139.86B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,197.92 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.70 | 634.77B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
258.39 | 458.24B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.13 | 323.72B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.32 | 294.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | アップグレード | Argus | Hold → Buy |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Underperform |
| 2026-02-20 | 開始されました | Barclays | Underweight |
| 2026-02-12 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-02 | 再開されました | Citigroup | Neutral |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Pfizer: Calling The BottomThe Patent Cliff Is Real, But The Valuation Has Fallen Too Far - Seeking Alpha
Former Pfizer HQ Evacuation Puts Office Conversions Under Structural Scrutiny - Yahoo Finance
Pfizer (NYSE:PFE) edges up as low-multiple pharma draws value notice this week - Kalkine Media
GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Is - Benzinga
Did FDA’s Priority Review of TALZENNA plus XTANDI in Earlier Prostate Cancer Just Shift Pfizer's (PFE) Investment Narrative? - Yahoo Finance
Pfizer: Board meeting tomorrow; Shares decline 0.62 percent - TradingView
Is Pfizer (PFE) Undervalued On Its FDA Priority Review In Prostate Cancer? - simplywall.st
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - GlobeNewswire Inc.
Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried. - Yahoo Finance
Pfizer stock stabilizes as oncology and vaccine pipeline shapes outlook - AD HOC NEWS
Full Fed. Circ. Urged To Reconsider Pfizer's Paxlovid IP Win - Law360
Pfizer’s ex-comms leader joins Vantage Data Centers - Medical Marketing and Media
Pfizer stock trades steadily as recent earnings and pipeline shape investor sentiment - AD HOC NEWS
How Investors May Respond To Pfizer (PFE) Prostate Cancer Combo Drug Label Expansion Push - simplywall.st
Samsung, Celltrion Join Nectin-4 ADC Race, Challenging Pfizer's Padcev Dominance - finance.biggo.com
Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer - The Globe and Mail
Pfizer building incident pits banner project with a conversion pitfall - The Real Deal
Pfizer (NYSE:PFE) Leads Healthcare Focus on Balance-Sheet Strength - Kalkine Media
Pfizer stock trades steady as Pfizer India posts stronger FY 2024 earnings - Ad-hoc-news.de
Arkansas Sues Pfizer, J&J, Others Over Drug Discount Access - Bloomberg Law News
Pfizer stock steadies as investors weigh pipeline progress and recent earnings - Ad-hoc-news.de
Pfizer Prevnar 20 by Pfizer Inc.broader adult protection in one syringe - Ad-hoc-news.de
Pfizer Inc (0Q1N) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
What Makes Pfizer (NYSE:PFE) Stand Out in the S&P 500? - Kalkine Media
Pfizer (PFE) Secures Priority Review for Talzenna in Prostate Ca - GuruFocus
Pfizer’s prostate cancer drug combination gets US FDA priority review - 1470 & 100.3 WMBD
Pfizer's prostate cancer drug combination gets US FDA priority review - Reuters
FDA accepts Pfizer filing for Talzenna-Xtandi prostate cancer use - Investing.com
Pfizer trial: TALZENNA combo cut progression-or-death risk 52% - Stock Titan
Bluesight Partners with Pfizer to Integrate SmartDose™ Source-Tagged Medications into KitCheck - HIT Consultant
Pfizer (PFE) Faces New Patent Lawsuits Over Covid 19 Vaccine Technology - simplywall.st
Biogen, Pfizer vet joins Formation Bio as CSO - The Pharma Letter
Pfizer (NYSE:PFE) Oncology Growth Faces A Major Valuation Test - Kalkine Media
Pfizer stock steadies as investors weigh post-COVID revenue mix and pipeline milestones - Ad-hoc-news.de
Sanofi reprimanded for disparaging Pfizer’s RSV vaccine - Fierce Pharma
Prevnar 20 by Pfizerbroader pneumococcal protection for adults - Ad-hoc-news.de
PFE Stock Quote Price and Forecast - CNN
Pfizer (PFE) Stock Seems Fairly Priced As Oncology Approvals Build - simplywall.st
PR News | Pfizer Pro Harnaga Takes Vantage Data PostTue., Jul. 21, 2026 - O'Dwyer's PR
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season - Yahoo Finance
8 Lessons I’ve Learned as a Cancer Survivor - Pfizer
Tingting Zhang-Kharas Appointed Vice President, Search & Evaluation, Oncology at Pfizer - hrtoday.in
Pfizer building’s collapse scare tests whether New Yorkers will forget and rent anyway - Crain's New York
From Vaccines to Air Traffic: Poland’s Billion-Euro Dispute with Pfizer - finchannel
Pfizer stock trades steady as recent earnings and pipeline updates frame valuation - Ad-hoc-news.de
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Pfizer Suspends Popular Menopause Cream in India - Benzinga
Axios C-Suite: Pfizer CEO on biotech's China warning - Axios
Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine - Yahoo Finance
Pfizer stock steadies as investors weigh recent earnings and pipeline progress - Ad-hoc-news.de
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
1.51%
大文字化:
|
ボリューム (24 時間):